NEW YORK — KromaTid, a genomics tools and services provider, and gene editing analysis firm SeQure Dx said on Friday that they have signed an agreement to comarket certain of their offerings for gene editing evaluation.
Under the terms of the deal, the companies will jointly offer KromaTid's dGH in-Site assay for single-cell, high-resolution, genome-wide DNA insert tracking, dGH Screen assay for de novo monitoring of structural variants throughout the genome, and Genomic Integrity Karyotyping service alongside SeQure's NoteSeQ platform for off-target site profiling and ScopeSeQ platform for assessing gene editing outcomes.
Additional terms of the arrangement were not disclosed.
"This joint offering provides a package that will empower scientists to predict and measure outcomes of gene editing across multiple platforms with the goal of minimizing risks to patients from the design stages and ultimately into the clinic," Keith Joung, scientific founder of SeQure, said in a statement.
In October, Longmont, Colorado-based KromaTid partnered with Noble Life Sciences on an analysis service to determine potential toxicity for novel cell and gene therapies prior to an investigational new drug application.
In March, Avance Biosciences struck a licensing deal for Waltham, Massachusetts-based SeQure's GUIDE-seq next-generation sequencing-based gene editing off-target analysis technology.